News, infos and good to know WKN: A2QQ2E ISIN: US45256X1037 Kürzel: IBRX Forum: Aktien User: Lirumlarum1

ImmunityBio (NASDAQ:IBRX) announces results from its Phase 1 study evaluating Anktiva (N-803), its IL-15 superagonist, in combination with Rituxan (rituximab) in certain patients with indolent non-Hodgkin lymphoma, a rare form of blood cancer. The study enrolled patients with iNHL (follicular lymphoma, marginal zone lymphoma, small lymphocytic lymphoma, lymphoplasmacytic lymphoma) that were relapsed or refractory after >2 prior lines of therapy. The combination regimen of Anktiva and Rituxan was well tolerated with a single reported grade 4 adverse event (AEs) and no reported grade 5 AEs. For patients with anti-CD20 mAb sensitive disease, the overall response rate (ORR) in the SQ cohort was 78% (7 of 9), while 7 of 7 (100%) responses in the SQ cohorts were complete remissions (CR).

ImmunityBio posts results from early-stage blood cancer study https://newsfilter.io/a/2f4366ef2ff3896515f13121b01e6d0f

On April 30, 2021, ImmunityBio, Inc. (the “Company”) entered into an Open Market Sale Agreement (the “Sale Agreement”) with Jefferies LLC (the “Sales Agent”) under which it may offer and sell up to $500,000,000 of shares of its common stock, par value $0.0001 per share (the “Shares”), from time to time through the Sales Agent, acting as the Company’s sales agent. The sales and issuances of the Shares under the Sale Agreement will be made pursuant to the Company’s effective shelf registration statement on Form S-3 (File No.333-255699) (the “Registration Statement”), that was automatically effective upon filing with the U.S. Securities and Exchange Commission (the “SEC”) on April 30, 2021. The offering is described in the Company’s Prospectus, as supplemented by a Prospectus Supplement dated April 30, 2021, as filed with the SEC on April 30, 2021 (together, the “Prospectus”).

SEC Filing, 30. April.

ImmunityBio, Inc. ImmunityBio, Inc. may offer, from time to time,    •  Common stock    •  Preferred stock    •  Debt securities    •  Warrants    •  Units We may from time to time, in one or more offerings, offer and sell common stock, preferred stock, debt securities, warrants to purchase common stock, preferred stock or debt securities, or any combination of the foregoing, either individually or as units comprised of one or more of the other securities. This prospectus provides a general description of the securities we may offer. This prospectus may not be used to sell securities unless accompanied by a prospectus supplement, which will describe the method and the terms of the offering. We will provide you with the specific amount, price and terms of the applicable offered securities in one or more supplements to this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. A prospectus supplement and any free writing prospectus may also add, update or change information contained in this prospectus with respect to that offering. You should read this prospectus, the information and documents incorporated, or deemed to be incorporated, by reference in this prospectus, and any applicable prospectus supplement and any related free writing prospectus carefully before you purchase any of our securities offered hereby. Our common stock is listed on the Nasdaq Global Select Market under the symbol “IBRX.” On April 29, 2021, the last reported sale price on the Nasdaq Global Select Market was $17.93 per share. There is currently no market for the other securities we may offer.

ImmunityBio has a comprehensive immunotherapy pipeline with more than 40 clinical trials (company sponsored or investigator initiated)—of which 25 are at Phase II and III stage of development—across 19 indications in solid and liquid cancers and infectious diseases. Currently 17 first-in human immunotherapy agents are in clinical testing and, to date, over 1,800 patients have been studied with our antibody cytokine fusion proteins, albumin chemo immunomodulators, Adeno and yeast vaccines and our off-the-shelf natural killer cell products. Anktiva™ (ImmunityBio’s lead cytokine infusion protein) is a novel interleukin-15 (IL-15) superagonist complex and has received Breakthrough Therapy and Fast Track Designations from the U.S. Food and Drug Administration (FDA) for BCG-unresponsive CIS non-muscle invasive bladder cancer (NMIBC). https://immunitybio.com/immunitybio-announces-launch-of-phase-2-trial-of-il-15-superagonist-anktiva-with-antiretroviral-therapy-to-inhibit-hiv-reservoirs/

June 10, 2021 at 9:30 Pacific Time is the IBRX Shareholders Meeting. I can't wait for the presentation and the positive fallout from the meeting.

ImmunityBio, Inc. @ImmunityBio 13 Std. ImmunityBio is continuously pursuing new immunotherapies designed to attack disease by enhancing the patient’s immune system, not weakening it. #ImmunityBio #CancerResearch $IBRX

ImmunityBio, Inc. @ImmunityBio 16 Std. Approximately 38 million people are living with AIDS globally; tens of millions of people have died since the epidemic began nearly 40 years ago. The goal of this study is to help inform a strategy towards inducing long-term HIV remission. $IBRX https://bit.ly/3gKUWyF

CULVER CITY, Calif.--(BUSINESS WIRE)--Apr. 29, 2021-- ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that the U.S. Military HIV Research Program (MHRP) at the Walter Reed Army Institute of Research has launched a Phase 2 clinical trial in Thailand to evaluate ImmunityBio’s interleukin-15 (IL-15) superagonist Anktiva® (also called N-803) administered in combination with antiretroviral therapy (ART) during acute HIV infection as an experimental therapy to target and inhibit early establishment of HIV ‘reservoirs’ in infected individuals. Researchers will compare levels of HIV RNA and DNA in lymph node samples pre- and post-treatment and evaluate the therapy’s effects on CD8+ T and natural killer (NK) immune cells. The study is being conducted at the Thai Red Cross AIDS Research Centre in Bangkok. The trial’s participants are being recruited through MHRP’s acute HIV infection cohort, which identifies individuals in the earliest post-infection stages. The cohort serves as a foundation to help researchers conduct investigations into long-term remission of HIV and to understand ways to suppress HIV without long-term antiretroviral treatment. “Our current strategy to not just treat but cure HIV infection involves both inducing HIV out of its latent state in host T cells and removing or killing infected cells via an immune response or immunotherapy,” said Patrick Soon-Shiong, M.D., Founder and Executive Chairman of ImmunityBio. “Anktiva is capable of triggering both of these mechanisms, as it can both activate viral transcription in CD4+ T cells—i.e., remove the virus from latency—and activate CD8+ memory cells and natural killer cells that recognize and kill HIV-infected host cells. We look forward to discovering whether or not this activity is correlated with reduction of viral load and inhibition of establishment of the HIV reservoir during acute infection in HIV.” In preliminary data from a separate Phase I study of Anktiva in HIV-infected subjects, the IL-15 superagonist was shown to be safe and to significantly activate proliferation of T cells and natural killer (NK) cells. There was also evidence that Anktiva activated viral transcription and reduced the viral reservoir in peripheral blood mononuclear cells. In addition, in foundational preclinical studies, ImmunityBio observed that Anktiva plus one or two anti-HIV broadly neutralizing antibodies, or bNAbs, suppressed simian/human immunodeficiency virus replication in 9 of 13 animals evaluated. Following these and other preclinical results, the AIDS Clinical Trials Group of the NIH is beginning a Phase I clinical trial (n=46) of Anktiva plus two bNAbs to explore whether the combination affects long-term viral remission. The clinical study is designed to investigate safety, tolerability and immunostimulatory effects of Anktiva administration during acute HIV infection. Anktiva will be administered subcutaneously at weeks zero, three and six and will be used along with antiretroviral therapy (ART) to determine whether Anktiva’s immunostimulatory effects reduce HIV titers during the acute stage of infection. The study duration is 12 weeks.

ImmunityBio Announces Launch of Phase 2 Trial of IL-15 Superagonist Anktiva With Antiretroviral Therapy to Inhibit HIV Reservoirs https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-announces-launch-phase-2-trial-il-15-superagonist?field_nir_news_date_value[min]=

In South Africa, the state-backed BioVac Institute plans to construct a plant at a cost of as much as $238 million after signing a manufacturing deal with U.S.-based ImmunityBio Inc., which is conducting Phase 1 vaccine trials in the country. That could act as a stepping stone toward developing a national inoculation export industry, BioVac Chief Executive Officer Morena Makhoana said last month. https://www.google.com/amp/s/www.bnnbloomberg.ca/ghana-drugmakers-approach-astrazeneca-about-local-vaccine-making-1.1595234.amp.html

Urology Times, April, 23. : Recombinant adenovirus 5 vaccine active in mCRPC A multitargeted recombinant adenovirus 5 (Ad5) vaccine platform was shown to be safe and clinically active in a phase 1 trial of patients with metastatic castration-resistance prostate cancer.1,2 ImmunityBio, Inc., the developer of the vaccine, reported in a press release that the second-generation human Ad5 (hAd5) immunotherapy vaccine targeting tumor-associated antigens (TAA) of prostate-specific antigen (PSA), MUC-1, and brachyury showed immune activation in 17 patients evaluated, with all participants mounting a T-cell response in at least 1 TAA. “The finding of T-cell–mediated immunity induced in 100% of 17 [patients with prostate cancer] whose white blood cells were evaluated in the study validates the ability of our hAd5 vaccine platform to generate a potent response to antigens delivered,” Patrick Soon-Shiong, MD, Founder and Executive Chairman of ImmunityBio, stated in the press release. “Furthermore, the demonstration that the vaccine can be administered repeatedly, without adverse effects at the dose of 5 × 1011 viral particles, supports the application of this hAd5 platform in both cancer and infectious diseases such as COVID-19. These early results, which include signals of clinical activity and durable stable disease, are encouraging for patients with highly resistant advanced metastatic prostate cancer and warrants further study,” added Soon-Shiong. The phase 1 study enrolled adult patients with radiologic evidence of progression or PSA progression. Patients received 3 vaccines concurrently, each targeting the 3 TAAs, every 3 weeks for a maximum of 3 doses in the dose de-escalation arm. Those treated in the dose-expansion arm also received a booster vaccine every 8 weeks for 1 year. The primary end point of the trial was determining the safety and recommended phase 2 dose. A partial response to therapy was reached by 1 patient, and 5 had stable disease for more than 6 months with confirmed PSA decline. The median progression-free survival was 22 weeks and the median overall survival (OS) was not reached. At 12 months, the rate of OS was 83.3%. The investigators observed a tolerable safety profile for the vaccine. There were no grade greater than 3 treatment-related adverse events or dose-limiting toxicities noted. Of note, 3 patients who achieved PSA response also had palliative radiotherapy. The investigators concluded that the vaccine’s efficacy will require further validation and its immunogenicity in combination with immuno-oncology and/or palliative radiation therapy is warranted. According to ImmunityBio, the hAd5 viral vector is also being used to develop vaccines to potentially treat other solid tumors including breast, pancreatic, lung, and head and neck cancers. The vaccines have shown their ability to overcome prior adenovirus immunity in preclinical models. https://www.urologytimes.com/view/recombinant-adenovirus-5-vaccine-active-in-mcrpc

ImmunityBio, Inc. @ImmunityBio 4 Std. Our investigational immunotherapy products are tailored to each patient’s needs. We employ a “triangle” offense designed to deliver durable, complete responses in cancer and infectious diseases. Learn more: https://immunitybio.com #ImmuntiyBio $IBRX

Mangel, Skepsis und Unsicherheit Afrikas steiniger Weg beim Corona-Impfen https://www.n-tv.de/22509672